Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Anbio Biotechnology
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-88.2% vs price
Base Case (Median)
-71.1% vs price
Bull Case (75th pct.)
-70.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.61 | -88.3% | High (40%) |
| PE Comparable | $3.37 | -35.1% | Medium (25%) |
| Graham Number | $1.53 | -70.6% | Medium (40%) |
| EV/EBITDA | $1.50 | -71.1% | Medium (20%) |
| Earnings Power Value | $0.38 | -92.7% | Medium (50%) |
Based on 5 out of 7 methods, NNNN appears overvalued at the current price of $5.19. The base case fair value of $1.50 implies 71.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.